Akero Therapeutics, Inc. (NASDAQ:AKRO) CFO William Richard White Sells 676 Shares

Akero Therapeutics, Inc. (NASDAQ:AKRO) CFO William Richard White sold 676 shares of the stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $44.88, for a total transaction of $30,338.88. Following the completion of the transaction, the chief financial officer now directly owns 61,959 shares of the company’s stock, valued at approximately $2,780,719.92. The trade was a 1.08 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Akero Therapeutics Trading Down 1.6 %

AKRO stock opened at $44.15 on Monday. Akero Therapeutics, Inc. has a 12 month low of $17.86 and a 12 month high of $58.40. The firm’s 50-day moving average is $42.10 and its 200 day moving average is $33.89. The company has a market capitalization of $3.52 billion, a PE ratio of -11.77 and a beta of -0.19. The company has a debt-to-equity ratio of 0.05, a current ratio of 17.25 and a quick ratio of 17.25.

Akero Therapeutics (NASDAQ:AKRO) last issued its earnings results on Friday, February 28th. The company reported ($0.99) EPS for the quarter, missing analysts’ consensus estimates of ($0.98) by ($0.01). On average, research analysts anticipate that Akero Therapeutics, Inc. will post -3.99 EPS for the current year.

Analyst Ratings Changes

AKRO has been the subject of several analyst reports. Canaccord Genuity Group raised their price objective on Akero Therapeutics from $56.00 to $73.00 and gave the company a “buy” rating in a research note on Tuesday, January 28th. Citigroup increased their price target on Akero Therapeutics from $65.00 to $80.00 and gave the company a “buy” rating in a report on Tuesday, January 28th. UBS Group boosted their price objective on shares of Akero Therapeutics from $42.00 to $109.00 and gave the company a “buy” rating in a research report on Friday, January 31st. Morgan Stanley restated an “overweight” rating on shares of Akero Therapeutics in a report on Sunday, March 2nd. Finally, HC Wainwright upped their price target on shares of Akero Therapeutics from $72.00 to $75.00 and gave the company a “buy” rating in a report on Monday, March 3rd. Nine investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $76.29.

Institutional Investors Weigh In On Akero Therapeutics

Several hedge funds have recently made changes to their positions in the company. GF Fund Management CO. LTD. bought a new stake in shares of Akero Therapeutics in the fourth quarter valued at about $41,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Akero Therapeutics by 18.3% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 71,451 shares of the company’s stock valued at $1,988,000 after purchasing an additional 11,035 shares in the last quarter. Woodline Partners LP lifted its position in shares of Akero Therapeutics by 29.9% in the 4th quarter. Woodline Partners LP now owns 379,967 shares of the company’s stock worth $10,571,000 after purchasing an additional 87,499 shares during the period. Two Sigma Advisers LP boosted its stake in shares of Akero Therapeutics by 195.7% during the fourth quarter. Two Sigma Advisers LP now owns 41,100 shares of the company’s stock valued at $1,143,000 after purchasing an additional 27,200 shares in the last quarter. Finally, Two Sigma Investments LP increased its holdings in Akero Therapeutics by 43.3% during the fourth quarter. Two Sigma Investments LP now owns 127,320 shares of the company’s stock valued at $3,542,000 after buying an additional 38,500 shares during the period.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.